News

Currently, ScienHub Research Support is offering assistance for two clinical trials underway in Spain under the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Sponsored by the University of Minnesota, European coordination is led by CHIP Copenhagen.

At the heart of this operation is the ScienHub Research Support’s CTU, responsible for orchestrating the study’s implementation at the Hospital Universitari Germans Trias i Pujol (HUGTiP). Their duties include executing visit procedures meticulously outlined in the protocol. Simultaneously, ScienHub Research Support’s CRO is diligently handling bureaucratic procedures and providing crucial management support. Furthermore, they are managing monitoring activities at various participating centers scattered throughout Spain.

Dr. Eugènia Negredo presents at #PostCROI some of the latest updates on aging and HIV discussed at #CROI2024, such as the REPRIEVE study, the first large-scale study to test a strategy aimed at preventing heart disease among HIV-positive individuals. The results of this study are likely to prompt changes in clinics, as they have shown that HIV-positive individuals taking Pitavastatin have a lower risk of developing cardiovascular issues. This represents crucial information that influences clinical practice and HIV management.

The SCHISTO-STOP study, aimed at implementing a screening strategy for schistosomiasis in immigrant populations at epidemiological risk, reveals promising preliminary results. Schistosomiasis is one of the most common helminthic infections worldwide, with serious health implications. In Catalonia, it is estimated that over 17,000 individuals are infected, yet only a small fraction have been diagnosed. Despite the existing treatment, Praziquantel, being safe and effective with cure rates exceeding 90%, many cases go unnoticed. Collaborative efforts between researchers and teams at ScienHub Research Support have enabled the study to be concluded on time, yielding promising results that could influence global strategies to enhance the quality of life for this vulnerable population group.

The PAX study consisted of a phase 2 clinical trial, randomized and double-blind, which prevented both the participant and the researcher from knowing which treatment the participant was receiving. This study has been one of the examples in which, thanks to the teamwork between the different departments of ScienHub Research Support and the good coordination of all parties involved, we have been able to meet the established deadlines and ensure good traceability of all data obtained.

ScienHub Research Support has played a key role in the clinical trials for the development of HIPRA’s vaccine, the first recombinant protein bivalent COVID-19 vaccine authorized in the European Union, ScienHub CTU has coordinated the implementation of the trials at the Germans Trias i Pujol Hospital site and has been the CRO responsable for the monitoring of one of HIPRA’s trials (RBDCOV project).

In a community screening study conducted in Metropolitana Nord Area, ScienHub Research Support team has played a crucial role supporting the on-site implementation coordination, providing support with the study documentation and authorities submission, and conducting the study monitoring visits. The results indicate that schistosomiasis is a common and underdiagnosed infection in the exposed population, with serious complications affecting the quality of life of those infected.

These findings underscores the need for healthcare policies to incorporate screening for this infection to enable early diagnosis and treatment, which could prevent complications and improve the quality of life for those affected.

The HOLA study will be offering a new intramuscular injectable medication every two months (Cabotegravir LA + Rilpivirine LA), at Primary Care Centers (CAP) and Community Centers.

The combination of Long-Acting Cabotegravir and Rilpivirine is the first injectable treatment for HIV to be approved in Spain, whose main importance resides in that it drastically reduces the frequency of administration in comparison with other available treatments, from daily to every two months. However, since its recent approval in Spain, this medication was only available in hospitals. ScienHub and the Fight Infections Foundation team are collaborating on the HOLA study, which gives now people living with HIV the opportunity to benefit from this treatment with more convenient and accessible options at the Checkpoint Community Center and Dr. Robert CAP. Furthermore, this is a multicenter study and involves healthcare centers located in Andalusia.